Compare Stocks: ZYBT, SIGA, ZNTL, and CRDL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$1.71 -1.2%	$1.72	$0.88 ▼ $2.34	$200.99M	0.79	1.28 million shs	889,558 shs
SIGA Siga Technologies	$3.45 +6.2%	$3.14	$2.83 ▼ $9.29	$233.51M	0.97	654,579 shs	1.17 million shs
ZNTL Zentalis Pharmaceuticals	$2.70 -1.8%	$3.95	$1.21 ▼ $6.95	$197.10M	1.85	911,757 shs	1.07 million shs
ZYBT Zhengye Biotechnology	$1.31 -0.4%	$1.74	$0.62 ▼ $8.01	$62.08M	-2.56	30,406 shs	19,338 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	-1.16%	-8.80%	-20.09%	+64.42%	+56.88%
SIGA Siga Technologies	+6.15%	+9.87%	+12.38%	-11.99%	-61.28%
ZNTL Zentalis Pharmaceuticals	-1.82%	-13.18%	-30.59%	-33.17%	+77.63%
ZYBT Zhengye Biotechnology	-0.38%	-4.74%	-28.69%	+82.93%	-73.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$1.71 -1.2%	$1.72	$0.88 ▼ $2.34	$200.99M	0.79	1.28 million shs	889,558 shs
SIGA Siga Technologies	$3.45 +6.2%	$3.14	$2.83 ▼ $9.29	$233.51M	0.97	654,579 shs	1.17 million shs
ZNTL Zentalis Pharmaceuticals	$2.70 -1.8%	$3.95	$1.21 ▼ $6.95	$197.10M	1.85	911,757 shs	1.07 million shs
ZYBT Zhengye Biotechnology	$1.31 -0.4%	$1.74	$0.62 ▼ $8.01	$62.08M	-2.56	30,406 shs	19,338 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	-1.16%	-8.80%	-20.09%	+64.42%	+56.88%
SIGA Siga Technologies	+6.15%	+9.87%	+12.38%	-11.99%	-61.28%
ZNTL Zentalis Pharmaceuticals	-1.82%	-13.18%	-30.59%	-33.17%	+77.63%
ZYBT Zhengye Biotechnology	-0.38%	-4.74%	-28.69%	+82.93%	-73.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDL Cardiol Therapeutics	2.50	Moderate Buy	$10.00	484.80% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A
ZNTL Zentalis Pharmaceuticals	2.40	Hold	$6.75	150.00% Upside
ZYBT Zhengye Biotechnology	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZYBT, SIGA, ZNTL, and CRDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
9/21/2026	CRDL Cardiol Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/16/2026	ZNTL Zentalis Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/26/2026	CRDL Cardiol Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/17/2026	CRDL Cardiol Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $10.00
8/11/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
7/23/2026	ZNTL Zentalis Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/20/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
7/17/2026	ZNTL Zentalis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
7/14/2026	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/6/2026	ZNTL Zentalis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.11 per share	N/A
SIGA Siga Technologies	$94.57M	2.62	$0.35 per share	9.76	$2.78 per share	1.24
ZNTL Zentalis Pharmaceuticals	$67.43M	2.87	N/A	N/A	$2.99 per share	0.90
ZYBT Zhengye Biotechnology	$16.64M	3.72	N/A	N/A	$0.93 per share	1.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	11/12/2026 (Estimated)
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.55%	-1.32%	11/5/2026 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	11/10/2026 (Estimated)
ZYBT Zhengye Biotechnology	-$9.98M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ZYBT, SIGA, ZNTL, and CRDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDL Cardiol Therapeutics	N/A	5.55	5.55
SIGA Siga Technologies	N/A	21.72	16.48
ZNTL Zentalis Pharmaceuticals	N/A	4.82	4.82
ZYBT Zhengye Biotechnology	0.03	1.14	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDL Cardiol Therapeutics	12.49%
SIGA Siga Technologies	55.40%
ZNTL Zentalis Pharmaceuticals	N/A
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
CRDL Cardiol Therapeutics	5.25%
SIGA Siga Technologies	2.73%
ZNTL Zentalis Pharmaceuticals	3.80%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDL Cardiol Therapeutics	18	116.18 million	110.08 million	Not Optionable
SIGA Siga Technologies	49	71.85 million	69.89 million	Optionable
ZNTL Zentalis Pharmaceuticals	106	71.67 million	68.95 million	Optionable
ZYBT Zhengye Biotechnology	269	47.39 million	N/A	N/A

ZYBT, SIGA, ZNTL, and CRDL Headlines

Recent News About These Companies

Zhengye Biotechnology Holding Ltd (ZYBT)

August 28, 2026 | ru.investing.com

Zhengye Biotechnology Regains Nasdaq Minimum Bid Price Compliance

August 6, 2026 | tipranks.com

Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up Today

August 5, 2026 | quiverquant.comQ

Zhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | Benzinga

July 23, 2026 | benzinga.com

Zhengye Biotechnology Addresses Unusual Nasdaq Trading Activity

July 21, 2026 | tipranks.com

Zhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)

July 21, 2026 | msn.com

Zhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading Activity

July 21, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

July 21, 2026 | globenewswire.com

Why Zhengye Biotechnology Holding Limited (ZYBT) Stock Is Up Today

July 20, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Ltd. Class A

July 13, 2026 | cnn.com

Zhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 Notice

June 4, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

June 4, 2026 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

April 28, 2026 | prnewswire.com

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026

April 6, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

April 6, 2026 | globenewswire.com

Zhengye Biotechnology Holding Ltd ZYBT

March 28, 2026 | morningstar.comM

Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM

March 25, 2026 | tipranks.com

Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM

February 23, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

February 11, 2026 | markets.businessinsider.com

Zhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder Letter

February 10, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT, SIGA, ZNTL, and CRDL Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

$1.71 -0.02 (-1.16%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.70 0.00 (-0.29%)

As of 09/25/2026 07:30 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Siga Technologies NASDAQ:SIGA

$3.45 +0.20 (+6.15%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$3.40 -0.05 (-1.33%)

As of 09/25/2026 07:56 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$2.70 -0.05 (-1.82%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$2.70 +0.00 (+0.19%)

As of 09/25/2026 07:40 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Zhengye Biotechnology NASDAQ:ZYBT

$1.30 -0.01 (-0.38%)

Closing price 09/25/2026 03:56 PM Eastern

Extended Trading

$1.30 0.00 (-0.38%)

As of 09/25/2026 07:30 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYBT, SIGA, ZNTL, and CRDL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYBT, SIGA, ZNTL, and CRDL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYBT, SIGA, ZNTL, and CRDL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT, SIGA, ZNTL, and CRDL Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

Siga Technologies NASDAQ:SIGA

Zentalis Pharmaceuticals NASDAQ:ZNTL

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYBT, SIGA, ZNTL, and CRDL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYBT, SIGA, ZNTL, and CRDL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYBT, SIGA, ZNTL, and CRDL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT, SIGA, ZNTL, and CRDL Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

Siga Technologies NASDAQ:SIGA

Zentalis Pharmaceuticals NASDAQ:ZNTL

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools